You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 3
  • #126 Real-world treatment, clinical and patient-reported outcomes in patients with newly diagnosed advanced ovarian cancer: up-date on the cumulative numbers of patients treated at the sites (NOGGO Ov54, NCT04830709)

Article Text

Article menu

Download PDFPDF

Poster/ePoster Sessions
06. Ovarian cancer
#126 Real-world treatment, clinical and patient-reported outcomes in patients with newly diagnosed advanced ovarian cancer: up-date on the cumulative numbers of patients treated at the sites (NOGGO Ov54, NCT04830709)
Free
  1. Jalid Sehouli1,2,
  2. Tjadina Arndt1,2,
  3. Klaus Pietzner1,2,
  4. Elena Iona Braicu1,2,
  5. Pauline Wimberger3,2 and
  6. Theresa Link3,2
  1. 1Department of Gynecology European Competence Center for Ovarian Cancer, Campus Virchow-Klinikum, Charité Medical University, Berlin, Germany
  2. 2North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany
  3. 3Department of Gynecology and Obstetrics, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany

Abstract

Introduction/Background The prospective, non-interventional study SCOUT-1 (NCT04830709; NOGGO ov54) evaluates real-world management of patients with primary advanced (FIGO stage III or IV) high-grade epithelial ovarian cancer (OC) to assess the effectiveness of standard treatment sequences used in routine clinical practice in Germany with focus on patients´ needs and health-related quality of life.

Methodology As described earlier, all initiated sites are asked once a year to provide cumulative data on their patients treated for OC. Additionally, site characteristics such as type, and certification were collected. Data analysis was done in a descriptive and explorative manner using appropriate statistical methods.

Results Out of 73 sites initiated by March 2023 55 sites provided their characteristics. Most sites are full-service hospitals (64%), 20% base service hospitals and 16% office-based gynecological sites. Most of the sites are certified from German Cancer Society as (gyneco)oncological centers (89%).

Cumulative data for 2022 were provided by 44 sites (35 also took part on last year questioning). Overall 24 patients with newly diagnosed OC were in mean treated by the sites in 2022 (range 5–96 patients). 14% of the sites treated < 1 patient/month, 59% 1–2 patients/month and 25% >2 patients/month. The sites mainly diagnosed advanced stage FIGO III or IV (72.0%), serous histology (71.0%) and high-grade carcinoma (72%). Cyto-reductive surgery was performed in 75.0% of the reported cases. Most of the patients received (72%) and if received, responded well to platinum-based chemotherapy (77%).

Conclusion Analysis of site specific, cumulative data showed similarity to other epidemiological sources in Germany. Compared to 2021 cumulative mean number of patients with newly diagnosed OC remains stable, even if there were some changes on a site level. Data from 2022 continues to support that a representative cohort of OC patients will be enrolled in the SCOUT-1 study.

Sponsor AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, in cooperation with North-Eastern German Society of Gynecological Oncology (NOGGO e.V.). Medical writing assistance was provided by Dr. Katharina Bakhaus, Alcedis

GmbH, Giessen

https://doi.org/10.1136/ijgc-2023-ESGO.515

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.